Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 6 of 6 clinical reviews.
Drake publicly confirmed Ozempic use in 2023, making him one of the first male celebrities to openly discuss GLP-1 therapy. Here the HealthRX Medical Team compares his disclosure to other public figures and layers rigorous clinical context on what these drugs actually do.
Read clinical reviewDrake confirmed Ozempic use in 2023. The HealthRX Medical Team breaks down what clinical research says about GLP-1 discontinuation, weight regain, and long-term maintenance strategies.
Read clinical reviewDrake confirmed Ozempic use in 2023. The HealthRX Medical Team maps the side effects he has publicly referenced against the FDA label and peer-reviewed GLP-1 receptor agonist trial data.
Read clinical reviewDrake publicly confirmed Ozempic use in 2023, making him one of the first male celebrities to do so openly. Here is what the HealthRX Medical Team says non-celebrity patients can actually learn from his public story about GLP-1 expectations, side effects, and discontinuation.
Read clinical reviewDrake confirmed Ozempic use in 2023. The HealthRX Medical Team breaks down what his GLP-1 regimen would actually cost a non-celebrity patient navigating insurance, pharmacy tiers, and prior authorization.
Read clinical reviewDrake confirmed Ozempic use in 2023. The HealthRX Medical Team breaks down what a real semaglutide prescribing protocol looks like for a male patient with his publicly documented profile.
Read clinical review